Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2001-03-23
2004-08-31
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C424S184100, C424S201100, C424S234100, C424S237100, C424S244100, C424S258100, C424S268100, C424S269100, C424S272100
Reexamination Certificate
active
06783765
ABSTRACT:
FIELD OF INVENTION
The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens. This vaccine is targeted against intracellular pathogens, more particularly the pathogen
Mycobacterium tuberculosis
and Salmonella in this case.
The utility of the present invention is to develop a vaccine against the intracellular pathogens, which are causative agents of tuberculosis, brucellosis, leishmaniasis, listeriosis, leprosy, malaria, typhoid, trypanosomiasis and streptococcus and HIV-infection. The pathogen
Mycobacterium tuberculosis
(
M. tuberculosis
) the subject matter of this invention is a causative agent of tuberculosis. In this invention
M. tuberculosis
was allowed to grow in the allogeneic and syngeneic macrophages and macrophage cell lines. The macrophages—
M. tuberculosis
complex was then irradiated to kill the macrophages as well as the mycobacterium.
BACKGROUND OF THE INVENTION
Tuberculosis is a chronic infectious disease that continues to kill some 3 million people a year. About 8 million new cases arise every year and the number continues to increase. About one-third of the world population is infected with
M. tuberculosis
. The emergence of AIDS has reactivated tuberculosis in millions of dormant individuals, causing a sharp rise in the number of cases and deaths.
M. tuberculosis
is therefore responsible for the highest morbidity rate among all infectious agents. The only available vaccine BCG is both unpredictable and highly variable. Doubtful efficacy of BCG vaccination has put the scientific community to urgently develop effective means of vaccination against the
M. tuberculosis
(Bloom, B. R. et. al., Annu. Rev. Immunol. 10:1992:453).
During the past many decades BCG has been extensively used as a vaccine world over. Several hundred million children and new born have been the recipient of BCG vaccine. However, in spite of wide usage of BCG vaccine, tuberculosis has still become the fastest spreading disease not only in developing countries but also in the industrialized world. Further, the protective efficacy of the current BCG vaccine is both unpredictable and highly variable and it remains the most controversial of all currently used vaccines. Its doubtful efficacy in controlled trials have increased the concern about its use as a vaccine (Bloom and Fine, Tuberculosis In B. Bloom (ed.), 1994:531, Bloom, B. R. et. al., Annu. Rev. Immunol. 10:1992:453). Furthermore, the extensive clinical trials done in Madras showed similar extent of protection in BCG-vaccinated and unvaccinated individuals, indicating that BCG induced zero protection (
Ind. J. Med. Res.
1980:72(Suppl.):1-74). Thus it is obvious that BCG vaccination does not prevent transmission.
In past also, many questions always arose pertaining to the safe use of BCG vaccine.
A major catastrophe that cast a cloud over the reputation of BCG vaccination occurred in 1929. In Lubeck, Germany, 251 children received a BCG vaccine prepared at a local institute, and 72 of these children died. Subsequent investigation revealed that the institute also maintained cultures of virulent tubercle bacilli and that the batch of BCG vaccine given to the children had accidentally been contaminated with one of these strains of
Mycobacterium tuberculosis
(Lubeck. 1935.
Die Sauglingstuberkulose in Lubeck
. Springer, Berlin).
A new question has arisen regarding the safety of BCG in HIV-infected individuals. A small number of cases of disseminated BCG-osis have been reported among children who received BCG vaccine and were subsequently found to be HIV seropositive (Von Reyn, et. al.
Lancet
1987: ii:669-672; Braun, et. al.,
Pedietr. Infect. Dis. J.
1992:11:220-227; Weltman, et. al.,
AIDS
7:1993:149). WHO currently recommends discontinuing the use of BCG vaccine in children showing overt signs of immunodeficiency (World Health Organization, 1992,
Expanded Program for Immunization, Program Report
,World Health Organization, Geneva;
Weekly Epidemiol. Rec.
62:1987:53).
Large volunteer studies by Dahlstrom and Difts (Scand J Respir Dis Suppl. 65:1968:35) and a meta-analysis of BCG in the prevention of tuberculosis based on 13 prospective studies and 10 case control studies has recently been completed (Colditz et. al., J. Amer. Med. Assoc. 271:1994:698-702). While it concluded that on average BCG was about 50% protective in preventing tuberculosis, the biological and operational significance of averaging, in essence, such widely divergent results are itself arguable.
Before the advent of AIDS, in most wealthy countries, the incidence of tuberculosis was declining for at least a century. This is illustrated in comparisons between The Netherlands (which never employed BCG vaccination) and the United Kingdom and Scandinavia (which instituted national BCG vaccination in the 1950). The declines in tuberculosis cases reported in these countries were similar (Styblo, K., Selected Papers R. Netherland Tuberc. Assoc. 24:1991:136; Sutherland, Bull. Int. Union. 57:1981:17). Thus it is unreasonable to attribute that the decline was due to BCG vaccination alone.
BCG's performance is based on a hypothesis that BCG is effective against primary infection in children and endogenous reactivation of long-standing infections but not against exogenous infection (ten Dam, H. G.
Adv. Tuberc. Res.
21:1984:79; ten Dam, H. G. and A. Pio.
Tubercle
63:1988:226). Epidemiological data suggest that BCG vaccination imparts greater or more consistent protection against systemic disease, in particular miliary tuberculosis and tuberculosis meningitis in children, than against pulmonary disease (Rodrigues, et.al., Int J epidemiol. 22:1993:1154). Lurie's studies indicated that the number of CFU of
M. tuberculosis
isolated from lungs of BCG-immunized versus unimmunized rabbits showed no difference in the number of organisms reaching and capable of being cultured from lung and other tissues.
Another insight is provided by the intracellular location of the mycobacterium. Electron microscopic findings indicate that BCG remains essentially entirely within the phagolysosomes after in vitro infection of macrophages, whereas virulent
M. tuberculosis
(strain H37Rv) can escape from the phagolysosome and enter the cytoplasm (McDonough, et.al.,
Infect. Immun.
61:1993:2763). This may be relevant insofar as it is the antigens in the endosomal compartment of antigen-presenting cells that are presented in conjunction with MHC class II determinants to CD4
+
T helper cells, whereas cytoplasmic antigens are presented in association with the Major Histocompatibility Complex (MHC) class I determinants to CD8
+
Cytotoxic T cells (CTL). If these findings in vitro are general, they will explain why
M. tuberculosis
is more dependent for its elimination on MHC class I-restricted CTL than BCG and suggests that BCG may not be very effective in eliciting MHC class I-restricted CTL (Stover, et.al., Nature 351:1991:456). In this context, Rich, 1951 (The Pathogenesis of Tuberculosis, 2
nd
, p. 1028; Charles C Thomas, Publisher, Springfield, Ill.), Canetti, 1955 (The Tubercule Bacilli in the Pulmonary Lesion of Man, p. 226; Springer, N.Y.) and Lurie, 1964 (Resistance to Tuberculosis. Experimental Studies in Native and Acquired Defense, p. 391; Harvard University Press, Cambridge Press, Cambridge, Mass.), commented that recovery from infection with
M. tuberculosis
provided stronger protection against future tuberculosis than could BCG.
The effective resistance to
M. tuberculosis
infection will require participation both of specific CD8
+
CTL to lyse macrophages or parenchymal cells unable to restrict their infection and of specific CD4
+
T cells able to produce IL-2, IFN-&ggr;, TNF-&agr;, and other lymphokines involved in macrophage activation.
Considering these drawbacks of the BCG-vaccine, the applicants have taken advantage of the fact that the vaccine will be used as an irradiated preparation and has no fear of inoculating in AIDS patients and immunocompromised childr
Agrewala Javed Naim
Sharma Naresh
Council of Scientific and Industrial Research
Renner John W.
Renner Otto Boisselle & Sklar
Swartz Rodney P
LandOfFree
Process for the preparation of a vaccine for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation of a vaccine for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of a vaccine for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3300314